Why Combine MEST-C, eGFR, Urine Protein and BP for IgA Risk?

It is common to feel stressed when waiting for a biopsy result, hoping it will give you a definitive answer about your long-term future. However, your biopsy score (the MEST-C score) is only one piece of the puzzle. While the biopsy provides a microscopic snapshot of the physical damage inside your kidney, your clinical tests—specifically your estimated glomerular filtration rate (eGFR), proteinuria (protein in the urine), and blood pressure—show how well your kidneys are functioning right now ^[1]. Doctors use all of these factors together because combining the structural evidence from your biopsy with your current clinical tests provides a much more accurate estimate of your risk than using either one alone ^{[1] [2]}.

Decoding the MEST-C Score

The MEST-C score is not a single number (like a severity grade out of 10) but a set of five separate categories based on looking at kidney tissue under a microscope. A pathology report usually lists them as individual components, such as M1, E0, S1, T0, C0.

• M (Mesangial hypercellularity, M0 or M1): Extra cells in the filter network of the kidney. This can predict the rate at which kidney function declines ^[3].
• E (Endocapillary hypercellularity, E0 or E1): Extra cells inside the tiny blood vessels of the filters. This lesion is associated with a more rapid loss of kidney function in patients who are not receiving immunosuppression ^[4].
• S (Segmental sclerosis, S0 or S1): Areas of scarring in some of the filters. It is independently associated with a steeper decline in eGFR ^[4].
• T (Tubular atrophy/interstitial fibrosis, T0, T1, or T2): Chronic scarring in the kidney tubes and supporting tissue. It is consistently the strongest predictor of long-term kidney survival ^[3]. Note that T0 does not mean zero scarring; it means the scarring is limited (affecting 0–25% of the area). T1 means 26–50%, and T2 means more than 50%.
• C (Cellular crescents, C0, C1, or C2): Crescent-shaped collections of cells that can predict lower kidney survival ^[4].

While repeat biopsy studies have shown that active lesions like E and C can respond to immunosuppressive medications ^[5], finding these lesions on a biopsy does not automatically mean you need an immunosuppressant. Treatment decisions depend on your overall clinical picture, including your eGFR trajectory, proteinuria levels, and current medical guidelines.

Furthermore, relying solely on the biopsy has important limitations:

• The Sampling Problem: A biopsy takes a tiny sample from a large organ. Because kidney damage can be patchy (focal), the needle might miss areas of damage simply by chance ^[6].
• A Single Snapshot: The biopsy only shows what the kidney looked like on the exact day the procedure was performed.
• Interpretation Variability: Different pathologists might score certain active lesions slightly differently, meaning some scores have subjective elements ^[6].

The Crucial Role of Clinical Markers

While the biopsy shows structure, clinical tests show function:

• eGFR: This estimates how well your kidneys are filtering waste from your blood.
• Proteinuria: Protein in the urine is a powerful prognostic marker. High levels indicate ongoing stress or persistent structural damage to the filters ^[7].
• Blood Pressure: High blood pressure is a modifiable risk factor that can contribute to further kidney damage.

These clinical markers change over time. A sustained reduction in proteinuria is associated with a lower long-term risk of kidney failure, though it is not a guarantee that the underlying physical damage has fully resolved ^{[8] [9]}.

The International IgAN Prediction Tool

To make sense of all this information, researchers developed the International IgAN Prediction Tool. This tool takes your information at the time of biopsy—including your MEST findings, eGFR, proteinuria, blood pressure, age, and medication use—to calculate a population-based estimate of your risk for a 50% decline in eGFR or the development of kidney failure over time (often up to 5 years) ^{[1] [10]}.

This tool does not dictate exact treatment prescriptions; rather, it supports shared decision-making by helping you and your doctor understand your overall risk profile, which can guide how closely you need to be monitored ^[11]. Note that a risk estimate is an estimate based on groups of similar patients, not a certainty about your individual fate.

Why Risk Assessment Must Evolve

A favorable biopsy cannot guarantee lifelong stability. In one long-term study, patients with excellent baseline kidney function (eGFR ≥60 mL/min/1.73 m²), low proteinuria (<1 g/day), and limited scarring (T0) on their biopsy were followed for a median of 22 years. Despite their low-risk baseline profiles, 18.6% eventually experienced a 50% GFR decline, and 2.8% developed kidney failure ^[12]. Baseline tests could not reliably distinguish which patients would ultimately progress ^[12].

This is why your initial risk estimate must be updated with your clinical trends. The original Prediction Tool was designed for use at the time of biopsy, but researchers have since developed updated models to reassess risk one or two years later ^[13]. Your disease is dynamic. How your proteinuria and eGFR respond to treatment over time adds critical prognostic information that a single past biopsy simply cannot provide ^[7].